HUMANA INC 8-K
Research Summary
AI-generated summary
Humana Inc. Reaffirms FY2026 EPS Guidance: ≥$8.89 GAAP, $9.00 Adj
What Happened
- Humana Inc. filed an 8-K (Regulation FD disclosure) on March 2, 2026, saying senior management will meet with investors and analysts between March 2 and March 31, 2026 and will reaffirm FY2026 earnings guidance.
- The company intends to reaffirm guidance of at least $8.89 in diluted GAAP earnings per share (EPS) and at least $9.00 in adjusted (non‑GAAP) EPS for the year ending December 31, 2026. The adjusted EPS reflects $0.15 for amortization of identifiable intangibles and a cumulative net tax impact of $(0.04).
Key Details
- Meeting window: March 2–31, 2026 (investor and analyst meetings).
- FY2026 GAAP EPS guidance: at least $8.89.
- FY2026 Adjusted (non‑GAAP) EPS guidance: at least $9.00 (GAAP $8.89 + $0.15 amortization − $0.04 tax impact).
- Company says it does not expect changes to the Adjusted EPS guidance but may update GAAP EPS guidance due to ongoing value creation and strategic initiatives.
- Disclosure signed by John‑Paul W. Felter, Senior VP, Chief Accounting Officer & Controller.
Why It Matters
- Guidance is a primary driver of investor expectations for Humana’s 2026 financial performance; reaffirming guidance signals management’s current confidence in meeting its targets.
- The filing highlights use of an adjusted (non‑GAAP) EPS metric; investors should consider both GAAP and non‑GAAP figures and the provided reconciliation when assessing results.
- The company warned the guidance is forward‑looking and subject to risks and uncertainties disclosed in its SEC filings, so outcomes could change.
Loading document...